About this trial
Rationale: Eosinophilic Granulomatosis with Polyangiitis (eGPA), eosinophilic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) are airway diseases where eosinophils and interleukine-5 are involved in the pathogenesis. eGPA differs from the other diseases with respect to involvement of other organs. The investigators hypothesize that nasal microbiome dysbiosis with a central augmenting role for S. Aureus plays an important role in disease expression. The investigators expect that anti-interleukin-5 treatment with mepolizumab restores the changes of the nasal microbiome and immune responses to a healthy control phenotype. To study this, the nasal microbiome, the local and systemic immune response and the effect of mepolizumab treatment will be assessed.
Eligibility criteria
Qualifiers
18 years of age
able to give informed consent
In CRSwNP group: availability of bilateral nasal polyps as diagnosed by endoscopy or CT scan
In Severe asthma group: clinical diagnosis of asthma with forced expiratory volume at one second(FEV1) <80% AND either FEV1 reversibility >12% initial or documented positive metacholine challenge (PC20 < 8 mg/ml)
Disqualifiers
unable to give informed consent
Active smoking < (less than) 6 months from baseline visit
Concomitant use of dupilumab within 6 months of baseline visit
pregnant or breastfeeding woman
Trial design
Treatments tested in this trial
- laboratory experiments before and after mepolizumab treatment
Treatment groups
Sponsors and collaborators
University Medical Center Groningen
Lead sponsor
GlaxoSmithKline
Collaborator